Design, synthesis, and biological evaluation of 3,3′-diindolylmethane N-linked glycoconjugate as a leishmanial topoisomerase IB inhibitor with reduced cytotoxicity†

IF 3.597 Q2 Pharmacology, Toxicology and Pharmaceutics
MedChemComm Pub Date : 2023-08-30 DOI:10.1039/D3MD00214D
Parampreet Kour, Pallavi Saha, Srija Bhattacharya, Diksha Kumari, Abhipsa Debnath, Amit Roy, Deepak K. Sharma, Debaraj Mukherjee and Kuljit Singh
{"title":"Design, synthesis, and biological evaluation of 3,3′-diindolylmethane N-linked glycoconjugate as a leishmanial topoisomerase IB inhibitor with reduced cytotoxicity†","authors":"Parampreet Kour, Pallavi Saha, Srija Bhattacharya, Diksha Kumari, Abhipsa Debnath, Amit Roy, Deepak K. Sharma, Debaraj Mukherjee and Kuljit Singh","doi":"10.1039/D3MD00214D","DOIUrl":null,"url":null,"abstract":"<p >Leishmaniasis, one of the neglected diseases, ranks second to malaria in the cause of parasitic mortality and morbidity. The present chemotherapeutic regimen faces the limitations of drug resistance and toxicity concerns, raising a great need to develop new chemotherapeutic leads that are orally administrable, potent, non-toxic, and cost-effective. Several research groups came forward to fill this therapeutic gap with new classes of active compounds against leishmaniasis, one such being 3,3′-diindolylmethane (DIM) derivatives. We tried to link this concept with another promising approach of glycoconjugation to study how glycosylated groups work differently from non-glycosylated ones. In the present study, a series of 3,3′-DIM derivatives have been synthesized and screened for their anti-leishmanial potency on <em>Leishmania donovani</em> promastigotes. Next, we synthesized the β-<em>N</em>,<em>N′</em> glycoside of potent compound <strong>3d</strong> using indole–indoline conversion, Fischer-type glycosylation, 2,3-dichloro-5,6-dicyano-1,4-benzoquionone (DDQ) oxidation, and molecular iodine catalyzed coupling with a suitable aldehyde in reasonable overall yield. The biological evaluation revealed that glycosides had reduced cytotoxic effects on the J774A.1 macrophage cell line. The enzyme inhibition study confirms that the glycoside derivatives have significant inhibitory activity against the leishmanial topoisomerase IB enzyme. Molecular docking further displayed the better binding efficiency of glycoside <strong>13</strong> with the target enzyme, suggesting the involvement of more H-bond interactions in the case of glycosides as compared to free drugs. Therefore, this work helps in proposing the fact that the addition of sugar moieties adds some favorable characteristics to free inhibitors, making it a promising approach for future clinical diagnostic and therapeutic applications, which can prove to be a valuable arsenal in combating such neglected diseases.</p>","PeriodicalId":88,"journal":{"name":"MedChemComm","volume":" 10","pages":" 2100-2114"},"PeriodicalIF":3.5970,"publicationDate":"2023-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"MedChemComm","FirstCategoryId":"3","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2023/md/d3md00214d","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Leishmaniasis, one of the neglected diseases, ranks second to malaria in the cause of parasitic mortality and morbidity. The present chemotherapeutic regimen faces the limitations of drug resistance and toxicity concerns, raising a great need to develop new chemotherapeutic leads that are orally administrable, potent, non-toxic, and cost-effective. Several research groups came forward to fill this therapeutic gap with new classes of active compounds against leishmaniasis, one such being 3,3′-diindolylmethane (DIM) derivatives. We tried to link this concept with another promising approach of glycoconjugation to study how glycosylated groups work differently from non-glycosylated ones. In the present study, a series of 3,3′-DIM derivatives have been synthesized and screened for their anti-leishmanial potency on Leishmania donovani promastigotes. Next, we synthesized the β-N,N′ glycoside of potent compound 3d using indole–indoline conversion, Fischer-type glycosylation, 2,3-dichloro-5,6-dicyano-1,4-benzoquionone (DDQ) oxidation, and molecular iodine catalyzed coupling with a suitable aldehyde in reasonable overall yield. The biological evaluation revealed that glycosides had reduced cytotoxic effects on the J774A.1 macrophage cell line. The enzyme inhibition study confirms that the glycoside derivatives have significant inhibitory activity against the leishmanial topoisomerase IB enzyme. Molecular docking further displayed the better binding efficiency of glycoside 13 with the target enzyme, suggesting the involvement of more H-bond interactions in the case of glycosides as compared to free drugs. Therefore, this work helps in proposing the fact that the addition of sugar moieties adds some favorable characteristics to free inhibitors, making it a promising approach for future clinical diagnostic and therapeutic applications, which can prove to be a valuable arsenal in combating such neglected diseases.

Abstract Image

Abstract Image

3,3′-二吲哚基甲烷N-连接糖缀合物作为利什曼原虫拓扑异构酶IB抑制剂的设计、合成和生物学评价,具有降低的细胞毒性†
利什曼病是一种被忽视的疾病,在寄生虫死亡率和发病率方面仅次于疟疾。目前的化疗方案面临着耐药性和毒性问题的局限性,迫切需要开发新的口服、有效、无毒和成本效益高的化疗药物。几个研究小组提出用新型抗利什曼病活性化合物填补这一治疗空白,其中一类是3,3′-二吲哚甲烷(DIM)衍生物。我们试图将这一概念与另一种有前景的糖缀合方法联系起来,以研究糖基化基团与非糖基化群体的工作方式有何不同。在本研究中,合成了一系列3,3′-DIM衍生物,并对其对杜氏利什曼原虫前鞭毛虫的抗利什曼病效力进行了筛选。接下来,我们使用吲哚-吲哚啉转化、Fischer型糖基化、2,3-二氯-5,6-二氰基-1,4-苯并醌(DDQ)氧化以及分子碘催化与合适的醛偶联,以合理的总产率合成了强效化合物3d的β-N,N′糖苷。生物学评价表明,糖苷类化合物对J774A.1巨噬细胞系的细胞毒性作用减弱。酶抑制研究证实糖苷衍生物对利什曼原虫拓扑异构酶IB酶具有显著的抑制活性。分子对接进一步显示了糖苷13与靶酶更好的结合效率,这表明与游离药物相比,在糖苷的情况下涉及更多的氢键相互作用。因此,这项工作有助于提出这样一个事实,即糖部分的添加为游离抑制剂增加了一些有利的特性,使其成为未来临床诊断和治疗应用的一种有前途的方法,这可以被证明是对抗这种被忽视的疾病的一个有价值的武器库。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
MedChemComm
MedChemComm BIOCHEMISTRY & MOLECULAR BIOLOGY-CHEMISTRY, MEDICINAL
CiteScore
4.70
自引率
0.00%
发文量
0
审稿时长
2.2 months
期刊介绍: Research and review articles in medicinal chemistry and related drug discovery science; the official journal of the European Federation for Medicinal Chemistry. In 2020, MedChemComm will change its name to RSC Medicinal Chemistry. Issue 12, 2019 will be the last issue as MedChemComm.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信